Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Repurposing Riluzole for Augmenting Brain-Derived Neuropathic Factor (BDNF) Levels and Cognitive Function in Patients Experiencing Cancer-Related Cognitive Impairment: An Interventional Pilot Clinical Trial

NCT06580002 is registered in ClinicalTrials.gov with University of California, Irvine as lead sponsor.

NCT NCT06580002
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06580002 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Repurposing Riluzole for Augmenting Brain-Derived Neuropathic Factor (BDNF) Levels and Cognitive Function in Patients Experiencing Cancer-Related Cognitive Impairment: An Interventional Pilot Clinical Trial
Lead sponsor
University of California, Irvine
Phase
Phase 2
Overall status
Recruiting
Start date
December 2, 2024
Completion date
December 31, 2027
Enrollment
75 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

brain cancer, breast cancer, colorectal cancer, gastric cancer, genitourinary cancer, gynecologic cancer, head and neck cancer, hodgkin lymphoma, kidney cancer, leukemia, liver cancer, lung cancer, lymphoid leukemia, melanoma, mycosis fungoides, myeloma multiple, non-hodgkin lymphoma, ovarian cancer, pancreas cancer, prostate cancer, sarcoma, urinary bladder cancer